Virtual screening method of xanthine oxidase inhibitory peptide
The virtual screening method was used to screen out highly active xanthine oxidase inhibitory peptides, which solved the problem of difficulty in finding high-active peptides in the existing technology, established a library of xanthine oxidase inhibitory peptides, found important active residues, and realized the oxidation of yellowing Rapid screening and prediction of purine oxidase inhibits peptides reduces the risk of adverse drug reactions.
Patent Information
- Application Number
- CN202411056214.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
It is difficult to quickly find highly active xanthine oxidase inhibitory peptides in the prior art, leading to adverse reactions caused by hyperuricemia treatment drugs, and existing drugs such as allopurinol and febuxstat may cause serious side effects during use.
Using virtual screening method, by selecting enzymes that can be used in the food industry, virtually enzymatically decompose pig visceral proteins, screen out biologically active peptides, and predict xanthine oxidation through molecular docking, constructing active peptide databases and establishing prediction models. Enzyme inhibits the activity of peptides and quickly obtains the xanthine oxidase inhibitory peptide library.
Successfully and quickly acquired the rich library of xanthine oxidase inhibitory peptides, found important active residues such as Phe(F) and Trp(W), established a prediction model, and achieved accurate prediction of xanthine oxidase inhibitory peptide activity and Screening reduces the risk of adverse drug reactions.
Smart Images

Figure CN118918959A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioactive peptide screening, and particularly relates to a virtual screening method for xanthine oxidase inhibitory peptides. Background Art
[0002] Hyperuricemia is a metabolic disease caused by an imbalance in the endogenous production and excretion of uric acid. It is the fourth most common basic metabolic disease after hypertension, hyperlipidemia and hyperglycemia. When the uric acid content in the human blood is greater than 7mg / dL or greater than 6mg / dL (for women), it will be diagnosed as hyperuricemia. Studies have shown that long-term hyperuricemia can cause certain damage to blood vessels, heart, liver and kidneys, and is closely related to the occurrence and development of metabolic syndromes such as hypertension, hyperlipidemia and hyperglycemia. Changes in modern lifestyle, such as excessive drinking, long-term intake of purine-rich foods, lack of exercise and sleep, may be one of the factors leading to the increased prevalence. Controlling purine intake or metabolism to uric acid and increasing the excretion of uric acid are currently effective methods to alleviate hyperuricemia. Since the efficacy of uricosuric drugs is strongly regulated by pharmacogenetics, regulating uric acid levels by targeting xanthine oxidase is still the safest and most effective means. Allopurinol and febuxostat are currently marketed uric acid-lowering drugs in my country that inhibit xanthine oxidase activity. Allopurinol has structural similarities to purine and can compete with purine to affect metabolism, thereby reducing uric acid. In clinical use, allopurinol causes hypersensitivity reactions in about 2% of patients, and in severe cases, death. In addition, allopurinol may also cause gastrointestinal intolerance, rash, and idiosyncratic reactions. Febuxostat is an effective non-purine inhibitor that may also cause adverse reactions during use, including upper respiratory tract infections, liver function, cardiovascular risks, and headaches. In order to resist the adverse reactions caused by drugs for the treatment of hyperuricemia, it is of great research and practical significance to explore new xanthine oxidase inhibitors from food. Summary of the invention
[0003] In view of the above-mentioned prior art, the present invention provides a virtual screening method for xanthine oxidase inhibitory peptides, which solves the problem that the prior art lacks the ability to quickly find highly active xanthine oxidase inhibitory peptides.
[0004] In order to achieve the above object, the technical solution adopted by the present invention is: to provide a virtual screening method for xanthine oxidase inhibitory peptides, comprising the following steps:
[0005] (1) Screening of active peptides: Enzymes that can be used in the food industry are selected to perform virtual enzymatic hydrolysis on porcine visceral proteins, all enzymatic peptides are retained, and enzymatic peptides with biological activity are evaluated and retained;
[0006] (2) Molecular docking: The crystal structure of xanthine oxidase is obtained from the public database of biological macromolecules. After removing water molecules and redundant ligands, the central coordinates of xanthine oxidase are determined according to the position of the original inhibitory ligand, and the peptide segment screened in step (1) is docked with xanthine oxidase;
[0007] (3) Construction of an active peptide database: A linear relationship between molecular docking binding energy and in vitro activity was established, and the in vitro xanthine oxidase inhibitory activity of other binding energies was obtained through a linear equation, thereby constructing a xanthine oxidase active peptide database;
[0008] (4) Establish a prediction model: Collect amino acid descriptors to establish the peptide structural feature variable matrix, and then use machine learning methods for statistical regression modeling.
[0009] (5) Generalization test: The activity of xanthine oxidase inhibitory peptides is predicted by the prediction model to obtain highly active xanthine oxidase inhibitory peptides.
[0010] The beneficial effects of the present invention are as follows: the present invention uses virtual screening to quickly obtain a variety of peptides from three visceral proteins of pigs, and combines molecular docking to efficiently establish a xanthine oxidase inhibitory peptide library. A linear equation between the binding energy and in vitro activity of the peptides is established, and the in vitro activity of other binding energies is successfully calculated. This provides a data basis for the subsequent analysis of the activity mechanism and the establishment of a prediction model.
[0011] Based on the above technical solution, the present invention can also be improved as follows.
[0012] Further, enzymes useful in the food industry are bromelain, proteinase K, subtilisin, papain, thermolysin and ficin.
[0013] Furthermore, the evaluation method was to use the PeptideRanker website to evaluate, and the score was provided on the probability of the peptide being biologically active in the range of 0 to 1, and peptides with a score greater than 0.5 were retained.
[0014] Further, amino acid descriptors include z-scales, VHSE, BLOSUM62, FASGAI, NNAAIndex, HESH, DPPS, Lin's scales, PtFP, E, G-SCALES, V, VHSEH, SVHEHS, TEN, SFED, ISA-ECI, VSW, SVTD, VSGETAWAY, MS-WHIM, SVRDF, C-scales, SVG, SVRG, SZOTT, ST-scales, VSTV, QTMS, T-scales, GRID, and SVEEVA.
[0015] Furthermore, the machine learning method is BPNN, PLS, MLR, RF, GMM or SVM
[0016] The beneficial effects of the present invention are as follows: the present invention finds the activity mechanism of xanthine oxidase inhibitory peptides by analyzing the amino acid composition and molecular docking diagram of four lengths of xanthine oxidase inhibitory peptides, and concludes that Phe (F) and Trp (W) are important active residues of xanthine oxidase inhibitory peptides, and Gly (G) effectively maintains the binding of Phe (F) and Trp (W) at both ends with the xanthine oxidase active site when the length of the peptide increases, thereby maintaining good xanthine oxidase inhibitory activity; and systematically compares 192 prediction model combinations, and finally obtains a prediction model with better prediction effect by linearly combining a single amino acid descriptor. The model is generalized and tested, which further confirms the prediction ability of the model. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is the binding energy distribution histogram of the tripeptide;
[0018] Figure 2 is the binding energy distribution histogram of the tetrapeptide;
[0019] Figure 3 is the binding energy distribution histogram of pentapeptide;
[0020] Figure 4 is the binding energy distribution histogram of the hexapeptide;
[0021] Figure 5 It is the difference diagram of the proportion of each amino acid in the two parts of the tripeptide;
[0022] Figure 6 It is the difference diagram of the proportion of each amino acid in the two parts of the tetrapeptide;
[0023] Figure 7 It is the difference diagram of the proportion of each amino acid in the two parts of the pentapeptide;
[0024] Figure 8 It is the difference diagram of the proportion of each amino acid in the two parts of the hexapeptide;
[0025] Fig. 9 This is a statistical diagram of the number of tripeptides bound to the active site;
[0026] Fig.10 This is a statistical diagram of the number of tetrapeptides bound to the active site;
[0027] Fig.11 This is a statistical diagram of the number of pentapeptides bound to the active site;
[0028] Fig.12 This is a statistical diagram of the number of hexapeptides bound to the active site;
[0029] Fig.13 The binding energy of the tripeptide and IC 50 Value relationships and linear equations;
[0030] Fig.14 The binding energy of the tetrapeptide and IC 50 Value relationships and linear equations;
[0031] Fig.15 The binding energy and IC of the pentapeptide 50 Value relationships and linear equations;
[0032] Fig.16 The binding energy of the hexapeptide and IC 50 Value relationships and linear equations. DETAILED DESCRIPTION
[0033] The specific implementation modes of the present invention are described in detail below with reference to the embodiments.
[0034] Example 1: Screening of active peptides
[0035] The protein information of three kinds of pig visceral proteins, namely, pig heart protein, pig liver protein and pig lung protein, was obtained from the UniProt database, as shown in Table 1.
[0036] Table 1 Protein information of pig visceral protein
[0037]
[0038] BIOPEP was used to perform virtual enzymatic hydrolysis on porcine visceral proteins. The enzymes used for virtual enzymatic hydrolysis were proteinase K, bromelain, subtilisin, papain, thermophilic protease and ficin. The virtual enzymatic hydrolysis function of BIOPEP allowed 1 to 3 enzymes to be performed simultaneously. After the above 6 enzymes were arranged and combined, there were 41 combinations. Porcine heart protein, porcine liver protein and porcine lung protein released 840120, 968903 and 1091275 peptides, respectively, containing 45112, 57312 and 53270 peptides, respectively. After removing duplicates, 89862 peptides were retained. PeptideRanker analysis predicted the bioactivity probability of 89,862 peptides, with scores ranging from 0.01762 to 0.982124. For fragments with high probability of bioactivity, a threshold of 0.5 was set, and a total of 14,544 peptides with high probability of bioactivity were screened out, with lengths ranging from 2 to 42. Except for lengths of 3 to 6, the proportion of other lengths was very low, which means low abundance in hydrolysates. Longer peptides are more difficult to synthesize and will consume a lot of time and cost. Therefore, peptides with lengths of 2 and greater than 7 were excluded, and peptides with lengths of 3-6 (11,498 types) were finally considered candidate peptides.
[0039] Example 2: Molecular docking
[0040] We commissioned a biotechnology company to synthesize candidate peptides and measured their in vitro inhibitory activity using the following methods:
[0041] The candidate peptide sample, xanthine and xanthine oxidase were dissolved in 1M Tris-HCl buffer to obtain 1.5mM xanthine solution, 0.1U·mL -1 xanthine oxidase solution; then 125 μL sample solution, 150 μL Tris-HCl buffer and 100 μL xanthine oxidase solution were mixed, reacted at 37°C for 15 min, 125 μL xanthine solution was added to continue the reaction for 20 min, and finally 150 μL dilute hydrochloric acid (1M) was added to stop the enzyme reaction, and the absorbance was measured at 295 nm. The calculation formula for xanthine oxidase inhibition rate is as follows:
[0042] Xanthine oxidase inhibition rate (%) = [1-(A1-A3) / (A2-A4)] × 100;
[0043] Wherein A1 is the absorbance after the mixed reaction of peptide sample, xanthine oxidase and xanthine; A2 is the absorbance after the reaction of xanthine oxidase and xanthine; A3 is the absorbance of sample and xanthine; A4 is the absorbance of xanthine solution.
[0044] Autodock vina was used to dock the potential peptides with xanthine oxidase. In Example 1, four peptides of different lengths were screened, namely, tripeptide, tetrapeptide, pentapeptide and hexapeptide. The docking binding energy distribution of each peptide length is shown in Figures 1 to 4 As shown in the figure, the binding energy of the tripeptides is less than -6 kcal / mol, and they contain fewer low-activity or inactive peptides. However, the tetrapeptides, pentapeptides, and hexapeptides all have a small number of peptides distributed in the low-activity part, and as the length increases, the peptides in the high-activity area begin to decrease, while the number of low-activity peptides begins to increase. This shows that as the length of the peptide increases, the probability of activity may begin to decrease.
[0045] Since the amino acid sequence and composition directly affect the binding site and stability of the peptide to xanthine oxidase, it plays an indirect role in determining the activity. In order to analyze the xanthine oxidase inhibition mechanism of these four lengths, they were divided into two parts. According to the binding energy of febuxostat (-8.3kcal / mol), the four lengths of peptides were divided into two parts: (1) less than -8.3kcal / mol; (2) greater than -8.3kcal / mol. Here, it can be considered that the peptides in part (1) are more potential xanthine oxidase inhibitory peptides, while the peptides in part (2) have lower xanthine oxidase inhibitory peptide activity potential. The amino acid composition of the peptides of each length in these two parts was analyzed.
[0046] Example 3: Construction of an active peptide database
[0047] Amino acid composition of peptides: Based on the frequency of occurrence of 20 amino acids at each position, the difference in the proportion of each amino acid in the two parts of the tripeptide is as follows: Figure 5 As shown in the figure, by comparison, it can be seen that Trp (W) is an important amino acid residue no matter where it is, and Phe (F) at both ends contributes more to the activity. Although Tyr (Y), Arg (R) and His (H) are not absolutely dominant amino acids, they still have a certain contribution to the activity of xanthine oxidase inhibitory tripeptide. The presence of Pro (P), Gly (G), Cys (C) and Met (M) will have a negative impact on the activity of xanthine oxidase inhibitory tripeptide.
[0048] The difference in the proportion of each amino acid in the two parts of the tetrapeptide is as follows Figure 6 As shown, by comparison, it can be seen that Phe (F) and Trp (W) have a greater contribution to the activity of xanthine oxidase inhibitory tetrapeptide when they are at the N-terminus and C-terminus, and Arg (R) and Tyr (Y) also have a certain contribution when they are at the N-terminus and C-terminus. In the middle position of the xanthine oxidase inhibitory tetrapeptide, Gly (G) has a more obvious contribution to the activity. In addition, Ala (A) and Ser (S) in the middle two positions are also beneficial to the activity of xanthine oxidase inhibitory tetrapeptide. In the presence of Ile (I), Ser (S), Met (M) and Pro (P), the activity of xanthine oxidase inhibitory tetrapeptide will be affected.
[0049] The difference in the proportion of each amino acid in the two parts of the pentapeptide is as follows Figure 7 As shown, by comparison, it can be seen that Gly (G) can have a positive effect on the xanthine oxidase inhibitory activity of the pentapeptide at any position, especially when it is in the middle position, the effect is significantly higher than other amino acids. At the N-terminus and C-terminus, Phe (F) also has a greater effect on the activity of the pentapeptide, and the effect is most obvious at the C-terminus. Trp (W) can only have a significant positive effect on the xanthine oxidase inhibitory activity of the pentapeptide at the C-terminus. In addition, Ala (A) and Ser (S) can play a certain positive role in the xanthine oxidase inhibitory activity when they are in the middle position. The presence of Pro (P), Met (M) and Ile (I) will have a negative effect on the xanthine oxidase inhibitory activity of the pentapeptide regardless of the position.
[0050] The difference in the proportion of each amino acid in the two parts of the hexapeptide is as follows Figure 8As shown, by comparison, it can be seen that the presence of Gly (G) at the N-terminus and the middle position has a positive effect on the xanthine oxidase inhibitory activity of the hexapeptide. In addition, Ser (S) and Ala (A) in the middle position will also have a positive effect on the xanthine oxidase inhibitory activity of the hexapeptide. When Phe (F) is at both ends, it helps the xanthine oxidase inhibitory activity of the hexapeptide. When the C-terminus is Trp (W), the xanthine oxidase inhibitory activity of the hexapeptide may be higher. When Pro (P), Met (M) and Ile (I) are present, the xanthine oxidase inhibitory activity of the hexapeptide may be affected.
[0051] Binding site analysis of peptides and xanthine oxidase: Hydrogen bonds play an important role in maintaining binding strength, so the number of hydrogen bonds generated between peptides and xanthine oxidase was mainly investigated. The molybdenum domain in xanthine oxidase is the key active site, which is surrounded by various amino acid residues. Xanthine oxidase inhibitors can prevent the activation of the active domain by interacting with these residues. The number of xanthine oxidase inhibitor tripeptides bound to the active site is as follows: Fig. 9 As shown, it can be found that these peptides can bind to the corresponding amino acid residues in the active site of xanthine oxidase, but the number of xanthine oxidase inhibitory tripeptides bound by the amino acid residues in the active site of xanthine oxidase is different. It can be found that the residues bound by the peptides containing dominant amino acids are concentrated on Gln767, Ser1080, Ser1082, Gln1040, Gln1194 and Thr1083.
[0052] The number of xanthine oxidase inhibitory tetrapeptides bound by the amino acid residues in the active site of xanthine oxidase varies, e.g. Fig.10 As shown, Ser1080, Thr1083, Gln767, Gln1040 and Lys1045 are sites with a large number of binding peptides, while Val1011, Thr1011, Ser1256, Lys1257, Gly799 and Glu767 only bind to one xanthine oxidase inhibitory tetrapeptide; it can be found that the residues bound by peptides containing dominant amino acids are also concentrated in Ser1080, Thr1083, Gln767, Gln1040 and Lys1045.
[0053] The number of xanthine oxidase inhibitory pentapeptides bound by the amino acid residues in the active site of xanthine oxidase varies, e.g. Fig.11As shown in the figure, Thr1083, Ser1080, Gln767 and Gln1040 are the sites that bind to the xanthine oxidase inhibitory pentapeptide more. However, Phe1010, Lys1257, His741, Glu126, Glu1209 and Gln585 can only produce hydrogen bonds with one group in the xanthine oxidase inhibitory pentapeptide; it can be found that the residues bound by the peptide containing the dominant amino acid are also concentrated on Thr1083, Ser1080, Gln767 and Gln1040.
[0054] Fig.12 It was shown that the sites that the xanthine oxidase inhibitory hexapeptide prefers to bind to are Arg912, Thr1083, Ser1080, Gln1194 and Glu1261. The main reason for the subtle changes in these binding sites is also related to the changes in the composition of the xanthine oxidase inhibitory hexapeptide. Compared with the xanthine oxidase inhibitory tripeptide, tetrapeptide and pentapeptide, Arg912 in the xanthine oxidase active center binds more peptides by hydrogen bonding. This may be related to the structure of Arg itself. Compared with other amino acids, Arg contains more amino groups, forming an important basis for the generation of hydrogen bonding. In addition, the amino acid residues in the two sites of Thr1083 and Ser1080 will bind more xanthine oxidase inhibitory peptides regardless of how the length of the xanthine oxidase inhibitory peptide changes. This indicates that these two residues are important binding residues in the active site of xanthine oxidase; similar to peptides of other lengths, Arg912, Thr1083, Ser1080, Gln1194 and Glu1261 are sites where peptides containing important amino acids are more likely to bind.
[0055] By comparing the amino acid composition and binding sites of xanthine oxidase inhibitory peptides of different lengths, it can be found that the amino acid composition and binding sites have changed. The most fundamental reason for this is that the change in amino acid composition caused the difference in other results. Table 2 shows the top 20 active peptides of each length and their binding energy. It can be found from the table that these highly active peptides almost all contain Phe (F) or Trp (W) residues, and as the length increases, these two residues tend to be distributed at both ends of the peptide. This is consistent with the results of the above analysis, and it also further confirms that Phe (F) or Trp (W) is the key to the activity of xanthine oxidase inhibitory peptides.
[0056] Table 2 The top 20 peptides with different lengths and their binding energies
[0057]
[0058]
[0059] Example 4: Building a prediction model
[0060] Considering that the database should contain peptides with different activities, all peptides with good docking binding energy were retained. Figures 1 to 4 It can be seen that the activity of peptides of each length has a normal distribution without gaps. By selecting peptides with different binding energies for synthesis and testing their xanthine oxidase inhibitory activity, the IC values of these peptides were established. 50 The linear equation between the corresponding binding energy and the peptide binding energy was used to calculate other peptide binding energies. Figures 13-16 As shown, the binding energy of xanthine oxidase inhibitory peptides is related to the in vitro activity IC 50 There is a good correlation between the R 2 They are 0.88 (tripeptide), 0.94 (tetrapeptide), 0.84 (pentapeptide) and 0.89 (hexapeptide) respectively.
[0061] The xanthine oxidase inhibitory tripeptides were characterized by 32 commonly used amino acid descriptors (z-scales, VHSE, BLOSUM62, FASGAI, NNAAIndex, HESH, DPPS, Lin's scales, PtFP, E, G-SCALES, V, VHSEH, SVHEHS, TEN, SFED, ISA-ECI, VSW, SVTD, VSGETAWAY, MS-WHIM, SVRDF, C-scales, SVG, SVRG, SZOTT, ST-scales, VSTV, QTMS, T-scales, GRID and SVEEVA), and six machine learning methods, BPNN, PLS, MLR, RF, GMM and SVM, were used to model the xanthine oxidase inhibitory tripeptides. The results of the 32×6 modeling combinations were compared and analyzed, among which R 2 The larger the RMSE, the better the prediction effect of the model. The smaller the RMSE, the closer the sample points predicted by the model are to the true value. This can help us find out which modeling combination has stronger prediction ability. 2 Compared with the RMSE value, it can be found that when using BPNN, PLS, MLR and GMM modeling, the modeling effect is unstable. 2 The values of RMSE will fluctuate greatly when the amino acid descriptors used change. Using RF and SVM, especially RF, can make the effect of each model stable. The best model is built using RF, and the amino acid descriptor applied is ST-scales. The worst model is the model built with PLS and character SFED.
[0062] Using the same modeling method as the tripeptide, it can be found that the results of the tetrapeptide and the tripeptide are similar, that is, RF and SVM may be more suitable for constructing a quantitative structure-activity relationship prediction model for xanthine oxidase inhibitory peptides. However, since the modeling effect of SVM fluctuates more at this time, RF may be more suitable for the modeling of xanthine oxidase inhibitory tetrapeptides. The best model for the tetrapeptide was established using RF, and the amino acid descriptor applied at this time was BLOSUM62. The worst model was the model established by PLS and character SFED.
[0063] Using the same method as the tripeptide modeling, the best model for the pentapeptide modeling was built using SVM, where the amino acid descriptor used was ST-scales, while the worst model was also the model built using PLS and character SFED.
[0064] Using the same modeling method as the tripeptide, the best modeling combination for the hexapeptide was the combination of the machine learning method RF and the amino acid descriptor HESH, and the worst was the combination of MLR and SFED.
[0065] Example 5
[0066] Generalization test: One of the purposes of establishing a prediction model for quantitative structure-activity relationship is to predict the activity of unknown compounds. Therefore, the best prediction model obtained above was used to predict the xanthine oxidase inhibitory peptides reported in the literature to verify the accuracy of the prediction model; the difference values predicted for tripeptides ranged from 0.3 to 8, and the difference ranges for tetra-, penta-, and hexapeptides were 0.03 to 13.6, 0.79 to 3.953, and 0.005 to 9.8, respectively. The experimental results are shown in Table 3.
[0067] Table 3 Results of ubiquitination test of xanthine oxidase inhibitory peptides of four lengths
[0068]
[0069] In summary, the prediction model of the four peptides can well distinguish between high-activity and low-activity peptides, which means that the model can quickly screen highly active xanthine oxidase inhibitory peptides and achieve the purpose of identifying the activity of potential xanthine oxidase inhibitory peptides.
[0070] Although the specific implementation of the present invention is described in detail in conjunction with the embodiments, it should not be understood as limiting the scope of protection of this patent. Within the scope described in the claims, various modifications and variations that can be made by those skilled in the art without creative work still fall within the scope of protection of this patent.
Claims
1. A virtual screening method for xanthine oxidase inhibitory peptides. It is characterized in that The following steps are involved: (1) Screening of active peptides: Enzymes that can be used in the food industry are selected to perform virtual enzymatic hydrolysis on porcine visceral proteins, all enzymatic peptides are retained, and enzymatic peptides with biological activity are evaluated and retained to obtain active peptides; (2) Molecular docking: The active peptides screened in step (1) were docked with xanthine oxidase using docking software, and the docking binding energy was calculated. At the same time, active peptides with different docking binding energies were synthesized and their xanthine oxidase inhibitory activity IC was determined. 50 ; (3) Construction of active peptide database: Establishment of molecular docking binding energy and IC 50 The linear relationship between the xanthine oxidase inhibitory activities in vitro and the xanthine oxidase active peptide database was constructed. (4) Establishing a prediction model: Collecting amino acid descriptors to establish a peptide structural feature variable matrix, and then using machine learning methods for statistical regression modeling; (5) Generalization test: The activity of xanthine oxidase inhibitory peptide is predicted by the prediction model to obtain the target xanthine oxidase inhibitory peptide.
2. The virtual screening method for xanthine oxidase inhibitory peptides according to claim 1, Features: The enzymes that can be used in the food industry are 1 to 3 of bromelain, proteinase K, subtilisin, papain, thermolysin and ficin.
3. The virtual screening method for xanthine oxidase inhibitory peptides according to claim 1, Features: The evaluation method is to use the PeptideRanker website to evaluate, and the score is to provide a score for the probability of the peptide having biological activity in the range of 0 to 1, and the peptides with a score greater than 0.5 are retained.
4. The virtual screening method for xanthine oxidase inhibitory peptides according to claim 1, Features: The amino acid descriptors include z-scales, VHSE, BLOSUM62, FASGAI, NNAAIndex, HESH, DPPS, Lin's scales, PtFP, E, G-SCALES, V, VHSEH, SVHEHS, TEN, SFED, ISA-ECI, VSW, SVTD, VSGETAWAY, MS-WHIM, SVRDF, C-scales, SVG, SVRG, SZOTT, ST-scales, VSTV, QTMS, T-scales, GRID and SVEEVA.
5. The virtual screening method for xanthine oxidase inhibitory peptides according to claim 1, Features: The machine learning method is BPNN, PLS, MLR, RF, GMM or SVM.
Citation Information
Patent Citations
Xanthine oxidase inhibitory peptide
CN111925412A
Fructus cannabis xanthine oxidase inhibitory peptide and preparation method thereof
CN114957391A
Soft-shelled turtle meat-derived ACE inhibitory peptide and screening method thereof
CN115873072A
Stichopus japonicus active peptide with alpha-amylase inhibition effect and application of stichopus japonicus active peptide
CN117247428A
Preparation method of xanthine oxidase inhibitory peptide and application of xanthine oxidase inhibitory peptide in preparation of uric acid reducing product
CN118146302A
Cited By
Method and system for discovering antioxidant peptide from food and agricultural by-products and outputting enzymolysis recommendation
CN121122400A
Method and equipment for screening xanthine oxidase inhibitory peptide
CN121747710A
